| 05.01.24 | With Mounjaro windfall, Lilly sets out to attract biotech partners; ARCH's $1.7B trio

Laden...

6 maanden geleden

Html
Tekst

Expanding Opportunities for T-Cell Engagers

AbCellera is leveraging its T-cell engager platform to generate molecules with potent tumor-cell killing and reduced cytokine release for multiple tumor targets, including peptide-MHCs. Explore more.

Today’s Big News

May 1, 2024

How Lilly is using its Mounjaro millions to position as biotechs’ ‘partner of choice’

Bob Nelsen on ARCH-led megarounds: ‘We want the IPO book in the seed round’

Pepper Bio spices up pipeline with $135M deal for G1 Therapeutics’ CDK4/6 inhibitor

Jacobio's KRAS data tee up safety-focused pitch for lung cancer market

Webinar: Mini-Organs, Major Breakthroughs: How Organoids Are Accelerating Oncology Drug Development

Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT

This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now.

Featured

How Lilly is using its Mounjaro millions to position as biotechs’ ‘partner of choice’

By James Waldron

Eli Lilly’s explosion into the weight loss space is proving fruitful for shareholders, but it’s also providing fresh opportunities for biotechs looking for a Big Pharma partnership.

Bob Nelsen on ARCH-led megarounds: ‘We want the IPO book in the seed round’

By Max Bayer

The three highest private biotech financings so far in 2024 totaled nearly $1.7 billion, led by Xaira Therapeutics’ $1 billion unveiling last week. One constant behind all three companies: ARCH Venture Partners.

Pepper Bio spices up pipeline with $135M deal for G1 Therapeutics’ CDK4/6 inhibitor

By James Waldron

With $6.5 million in seed funding, Pepper Bio has decided to shake up its portfolio by acquiring a CDK4/6 inhibitor from G1 Therapeutics.

Jacobio's KRAS data tee up safety-focused pitch for lung cancer market

By Nick Paul Taylor

Jacobio Pharma is making a play for the Chinese KRAS market, unveiling registrational lung cancer data that suggest its asset can hold its own on efficacy and may have advantages on safety and tolerability.


A message from Digital Pharma Engage

J&J subsidiary floats $6.48B settlement to resolve thousands of claims that its talc products caused ovarian cancer

By Fraiser Kansteiner

J&J’s subsidiary LLT Management has drafted a proposed “Plan of Reorganization” that—if confirmed—would see J&J pay ovarian cancer claimants roughly $6.48 billion over 25 years to resolve 99.75% of its remaining talc lawsuits in the U.S.

FTC targets Novo's Ozempic, others in crackdown on 300-plus 'junk' patent listings in FDA database

By Angus Liu

The U.S. FTC is not done with its crackdown on what it views as improper listing of patents in the FDA Orange Book. After an initial round of challenge launched in November against more than 100 patents, the FTC is back targeting another 300-plus patent listings by eight pharma firms.

GSK and Genomics collab to explore using genetics in clinical trial design

By Helen Floersh

GSK and Genomics will collaborate on a new precision medicine initiative that assesses how polygenetic risk scores can be used to improve clinical trial design.

BIO survey to elucidate US biopharma’s reliance on Chinese CDMOs amid decoupling threats

By Angus Liu

Facing a push for China-U.S. decoupling from Washington, the industry trade group BIO now wants to quantify the U.S.’s dependence on Chinese CDMOs through a survey.

Hospitals no longer required to report COVID-19 data to CDC

By Dave Muoio

Hospitals were required to share COVID-19 admissions, ICU capacity and other related data on a daily basis during the height of the COVID-19 pandemic, then the reporting frequency shifted. The CDC said it still encourages hospitals to report their data on a "voluntary" basis and will soon begin displaying those data online.

Fierce podcasts

Don’t miss an episode

'The Top Line': A look at pharma revenue rankings

This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report.

'Podnosis': A mobile clinic, free scans and the search for long COVID answers

'The Top Line': Winning formulas for the best biotech and drug names


A message from Fierce Pharma Forward

Resources

Whitepaper

Branded Digital Companions in Biopharma

This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion.

Presented by: Blue Matter, strategic consultants in the life sciences

Whitepaper

Vaccine Development Challenges in Facing Influenza and COVID-19

Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead.

Sponsored by: PPD®️ Laboratory Services

eBook

Designing Patient-Centered Endpoint in Rare Disease Trials

To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time.

Patient Engagement Series

Discover the secrets behind successful patient engagement

Antibody Profiling: Decoding the Humoral Immune System

Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today!

Straight to Market in an Autoinjector

The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.

Presented by Lonza

eBook

Discover the future of mAb manufacturing

Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes.

Oncology Market Outlook 2024

This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Guidance for Biotechs Choosing Next-Gen Contract GMP/CMC Labs

Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future.

Sponsored by: PPD®️ Laboratory Services